What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.”In the company’s words, NCT06947109 on ClinicalTrials.gov
- Main trialPhase 1
- “This is a phase I clinical study on dose escalation evaluating the safety, tolerability, PK and PD of a single dose of AK139 administered subcutaneously in healthy subjects.”In the company’s words, NCT06947109 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 30 Jan 2026 | A Clinical Study of AK139 in Healthy Subjects | |
| Phase 3Completed | 19 Aug 2024 | A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | 19 Feb 2025 | A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis | |
| Phase 2Completed | 25 Apr 2022 | A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis | |
| Phase 2Completed | 3 Feb 2023 | A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis | |
| Phase 2Completed | 11 Dec 2024 | To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis | |
| Phase 1Completed | 9 Sep 2019 | A Study of AK111 in Healthy Subjects | |
| Phase 1Completed | 2 Mar 2021 | A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026